The European Parkinson’s Disease Association (EPDA) has launched the third and final booklet in its Life with Parkinson’s series. This latest edition concludes a four-year awareness campaign, which aims to highlight the lack of understanding and knowledge concerning Parkinson’s that exists throughout Europe today. The booklet’s launch, in Amsterdam, the Netherlands, was one of the many activities in a weekend dedicated to celebrating the organisation’s 20th anniversary year and its commitment to improving the lives of people with Parkinson’s (PwPs).
To view Multimedia News Release, go to http://www.multivu.com/mnr/56619-epda-launches-life-with-parkinsons-booklet
Diabetes experts met and determined that some self-monitoring blood glucose (SMBG) systems, despite meeting accuracy standards at the time of U.S. Food and Drug Administration (FDA) clearance, fail to consistently meet accuracy standards once on the market, potentially putting patient health at risk. In a public meeting convened by the Diabetes Technology Society on May 21, 2013, in Arlington, Virginia, leading academic clinicians, clinical chemists, medical device experts, patient advocates and FDA representatives reviewed a growing body of peer-reviewed research demonstrating that the performance of some blood glucose monitors on the market may not be meeting accuracy standards.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/61870-diabetes-technology-society-inaccurate-blood-glucose-monitors-risky
As millions of Americans begin choosing a health plan for the first time under the Affordable Care Act, the new Healthgrades American Hospital Quality Outcomes 2014: Report to the Nation released today reveals how hospital selection can dramatically impact a patient’s health. The report demonstrates that individuals are far more likely to die or suffer complications at hospitals receiving the lowest Healthgrades rating. In fact, each year an estimated 234,252 lives could potentially be saved and 157,418 complications could be avoided if all hospitals performed similarly to the highest rated hospitals.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63942-healthgrades-american-hospital-quality-outcomes-2014-report-to-the-nation
In recent years there has been a shift in the understanding of cancer. Immunotherapy with vaccines has been emerging as the most promising direction towards a decisive improvement of treatment outcomes.
The Dendritic Cell Vaccine has received FDA approval for prostate cancer and trials are now under way for a variety of other cancers. These vaccines are usually administered on their own.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64654-issels-integrative-immunotherapy-for-standard-therapy-resistant-cancers
The following statement is being issued by Jonathan Schochor, Chairman, Plaintiffs’ Steering Committee, regarding Jane Doe No. 1, et. al. v. Johns Hopkins Hospital, et al., No. 24-C-13-001041.
If you were a patient of, or treated by Johns Hopkins Hospital gynecologist, Dr. Nikita Levy, you are a member of a mandatory settlement class action.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65136-dr-nikita-levy-class-action-lawsuit-johns-hopkins-hospital-gynecology
Evidence from the Childhood Cancer Survivor Study suggests that changes in childhood cancer treatment have reduced deaths from the late effects of cancer treatment and extended the lives of childhood cancer survivors. St. Jude Children’s Research Hospital investigators led the research, which will be presented today at the plenary session of the 2015 annual meeting of the American Society of Clinical Oncology (ASCO).
The study is one of four being featured at the plenary session press briefing, which highlights research that ASCO deems as having the highest scientific merit and greatest potential to affect patient care.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7532851-st-jude-cancer-research/
C. R. Bard, Inc. today announced the publication of RESILIENT trial results by Circulation: Cardiovascular Interventions showing the Bard LifeStent® Vascular Stent improved patency and reduced revascularization rates in patients with moderate-length lesions in the superficial femoral artery (SFA) and proximal popliteal artery compared to patients treated with percutaneous transluminal angioplasty (PTA).
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/bard/44623/
After a successful pilot program in October 2009, Cancer Treatment Centers of America (CTCA) is introducing an innovative approach to cancer treatment this July at each of its four hospitals in suburban Chicago, Philadelphia, Tulsa and suburban Phoenix. Called “Patient Empowered CareSM,” this advancement in the patient treatment delivery process offers patients an average of between two and three hours with a dedicated team of specialized oncology physicians and clinicians.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cancercenter/44523/
Close-Up TV News recognizes the Orthopaedic & Spine Institute for its remarkable commitment to quality care, providing relief to thousands of patients.
Spine surgery has advanced significantly over the past decade, allowing for more reliable outcomes, less surgical morbidity and quicker recovery. Dr Steven Cyr of the Orthopaedic & Spine Institute in San Antonio (http://www.saspine.com) offers some of the country’s most advanced training, compassionate care and individualized treatment options to help eliminate back and neck pain and improve his patients’ quality of life.
To view MultiMedia News Release, go to http://multivu.prnewswire.com/mnr/closeuptvnews/46410/
A study published in the Journal of Infectious Diseases indicates that treatment with oseltamivir significantly reduces mortality in patients with influenza A/H5N1, or ‘bird flu,’ even when given late in the course of illness.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/outcome/46648/
While the government claims to provide pricing for drugs and procedures, those listings only highlight what Medicare and Medicaid are willing to reimburse, not what those services actually cost. Hospitals, doctors and insurance companies provide patients with an itemized bill for care – but only AFTER the fact. The Healthcare Transparency Index, issued today by change:healthcare, is the first to provide healthcare consumers with ongoing trends data about actual healthcare costs – offering insight into critical opportunities for cost savings.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/changehealthcare/46792/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company’s novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection (CDI). The Phase 3 trial showed that fidaxomicin significantly reduced recurrence rates and increased global cure rates when compared to vancomycin, the only treatment approved by the U.S. Food and Drug Administration for CDI. The article titled,
